Fennec Pharmaceuticals (FENC) Set to Post Earnings on Tuesday

Fennec Pharmaceuticals (NASDAQ:FENC - Get Free Report) is scheduled to be issuing its quarterly earnings data before the market opens on Tuesday, May 14th. Analysts expect the company to announce earnings of $0.49 per share for the quarter.

Fennec Pharmaceuticals (NASDAQ:FENC - Get Free Report) last announced its quarterly earnings results on Thursday, March 21st. The company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of $0.02 by ($0.12). The company had revenue of $9.74 million for the quarter, compared to analysts' expectations of $9.47 million. On average, analysts expect Fennec Pharmaceuticals to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Fennec Pharmaceuticals Stock Performance

Shares of FENC stock traded down $0.08 during mid-day trading on Wednesday, hitting $9.27. 38,946 shares of the stock were exchanged, compared to its average volume of 111,487. The stock's fifty day simple moving average is $10.07 and its two-hundred day simple moving average is $9.57. Fennec Pharmaceuticals has a 12-month low of $6.30 and a 12-month high of $11.92. The stock has a market capitalization of $253.26 million, a price-to-earnings ratio of -15.20 and a beta of 0.45.

Insider Buying and Selling at Fennec Pharmaceuticals

In other news, COO Adrian Haigh sold 22,223 shares of the company's stock in a transaction that occurred on Monday, April 22nd. The stock was sold at an average price of $9.32, for a total transaction of $207,118.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Fennec Pharmaceuticals news, CFO Robert Andrade sold 13,975 shares of the business's stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $11.00, for a total transaction of $153,725.00. Following the transaction, the chief financial officer now owns 105,746 shares in the company, valued at approximately $1,163,206. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Adrian Haigh sold 22,223 shares of the stock in a transaction that occurred on Monday, April 22nd. The stock was sold at an average price of $9.32, for a total value of $207,118.36. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 193,093 shares of company stock worth $1,984,921. 11.25% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

FENC has been the topic of a number of research reports. Craig Hallum raised their price target on Fennec Pharmaceuticals from $17.00 to $18.00 and gave the stock a "buy" rating in a research note on Monday, March 18th. HC Wainwright lifted their target price on shares of Fennec Pharmaceuticals from $17.00 to $18.00 and gave the company a "buy" rating in a report on Thursday, April 4th. Finally, Wedbush reiterated an "outperform" rating and set a $16.00 price target on shares of Fennec Pharmaceuticals in a research note on Monday, March 18th.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.